Examiner Cite

No

Initial*

Patent Number

Kind

publisher, city and/or country where published.

Code¹

Issue Date

Remove

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

	Application Number		09695216		
	Filing Date		2000-10-25		
NFORMATION DISCLOSURE TATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor Grego		gory J. Lauckhart		
	Art Unit		2442		
	Examiner Name	John	Moore Jain Macilwinen		
	Attorney Docket Number		20184/NNR11		

U.S.PATENTS

Name of Patentee or Applicant

of cited Document

	1									
If you wisl	h to ac	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite I	No Publication Number	Kind Code ¹	Publica Date	Name of Patentee or Application of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
If you wis	1 h to ac	dd additional U.S. Publ	ished An	polication	citatio	n information r	slease click the Ad	i butto	on Add	
,,						ENT DOCUM			Remove	_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1									
If you wisl	h to a	l dd additional Foreign F	atent Do	cument	citation	information pl	lease click the Add	buttor	n Add	_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner	Cite	Include name of the a								тя

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Initials* No

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date		09695216	
		2000-10-25	
First Named Inventor	Grego	ry J. Lauckhart	
Art Unit		2442	
Examiner Name	John	Moore Jain Macilwinen	
Attorney Docket Number		20184/NNR11	

Shruj Tanaka, The Development of Mullimedia Buseness (the 29td), Buseness Communication, Japan, Buseness Communication Corporation, February 1, 1989, Vol. 35, No. 2, 1992 115-122 - Olden Inparises Patel Office Notice of Reasons for Rejection' issued on September 6, 2010, Translation of Japanese Notice oited as NPL 2 in Information Disclosures. Schement filled on Enfertuary 28, 2010.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kins Codes of USPTO Patient Documents at users USPTO_GOV or MECP 901.4. ² Enter office that issued the document, by the Nov-little code (NIPO) Standard ST3. ³ Sor Juspanese patient document, by the Option of the year of the Proprior many species the section all number of the patient of the Proprior many species are all number of the patient document, ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if English Impriscate Installation is attacked.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09695216	
Filing Date		2000-10-25	
First Named Inventor Gregoria		ory J. Lauckhart	
Art Unit		2442	
Examiner Name John		Moore Jain Macilwinen	
Attorney Docket Number		20184/NNR11	

57 993

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith.

SIGNATURE

Michael W. Zimmerman

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.								
Signature	/ Michael W. Zimmerman/	Date (YYYY-MM-DD)	2013-05-10					

Registration Number

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Comments of December 1.00 and 1.00 Accessed, New York 1.00 Accessed 1.00 Ac

Name/Print

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicide to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested process andior examine your submission related to a patient application or patient. If you do not furnish the requested required to the procession of the submission, which may result in fearning-time of proceedings or a banderiness of the separation of the submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.